Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Breese Hall.
Gripe: vacunar o no.
Pediatrics, 23 (1987), pp. 205-207
[2.]
J.M. Vilanova Juanola.
La vacuna de la grip. Creences, mites i costums.
Pediatr Catalana, 56 (1996), pp. 309-310
[3.]
K.M. Neuzil, B.G. Mellen, P.F. Wright, E.F. Mitchel Jr, M.R. Griffin.
The effect of Influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.
N Engl J Med, 342 (2000), pp. 225-231
[4.]
H.S. Izurieta, W.W. Thompson, P. Kramarz, D.K. Shay, R.L. Davis, F. DeStefano, et al.
Influenza and the rates of hospitalization for respiratory disease among infants and young children.
N Engl J Med, 342 (2000), pp. 232-239
[5.]
K. Mcintosh, T. Lieu.
Is it time to give Influenza vaccine to healthy infantsα.
N Engl J Med, 342 (2000), pp. 275-276
[6.]
CDC. Prevention and control of Influenza: recommendations of the ACIP.
Mmwr, 49 (2000), pp. 1-38
[7.]
W.P. Glezen, W.A. Keitel, L.H. Taber, P.A. Piedra, R.D. Clover, R.B. Couch.
Age distribution of patients with medically-attended illnesses caused by sequential variants of Influenza A/H1N1: comparison to age-specific infection rates, 1978-1989.
Am J Epidemiol, 133 (1991), pp. 296-304
[8.]
H.W. Kim, C.D. Brandt, J.O. Arrobio, B. Murphy, R.M. Chanock, R.H. Parrott.
Influenza A and B virus infection in infants and young children during the years 1957-1976.
Am J Epidemiol, 109 (1979), pp. 464-479
[9.]
F.M. Munoz, J.R. Campbell, R.L. Atmar, J. García-Prats, B. Baxter, L.E. Johnson, et al.
InfluenzaA virus outbreak in a neonatal intensive care unit.
Pediatr Infect Dis J, 18 (1999), pp. 811-815
[10.]
X. Sagrera, G. Guinovart, F. Raspall, N. Rabella, E. Moliner, P. Sala, et al.
Infecció per virus de la grip A en unitats neonatals.
Pediatr Catalana, 60 (2000), pp. 79-80
[11.]
R.J. Cunney, A. Bialachowski, D. Thornley, F. Smaill, R.A. Pennie.
An outbreak of Influenza a in a neonatal intensive care unit.
Infect Control Hosp Epidemiol, 21 (2000), pp. 449-454
[12.]
M. Campins, M. Torres, J.M. Bayas, C. Serra, M. Bruguera.
La vacunación del personal sanitario.
Med Clin (Barc), 113 (1999), pp. 583-591
[13.]
Comité Asesor de Vacunas de la Asociación Española de Pediatría. Manual de Vacunas 2000 (en prensa)
[14.]
American Academy of Pediatrics. Influenza.
2000 Red Book: Report of the Committee on Infectious Diseases (25. a ed.), pp. 351-359
[15.]
J.M. Vilanova Juanola.
Vacuna antigripal.
Vacunas 1998, pp. 71-97
[16.]
Einsa Ediciones Informatizada S.A, (2000),
[17.]
T. Lasky, G.J. Terracciano, L. Magder, C.L. Koski, M. Ballesteros, D. Nash.
The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 Influenza vaccines.
N Engl J Med, 339 (1998), pp. 1797-1802
[18.]
N.J. Cox, K. Subbarao.
Influenza.
Lancet, 354 (1999), pp. 1277-1282
[19.]
A. Malhotra, L.R. Krilov.
Influenza and respiratory syncytial virus. Update on infection management and prevention.
Pe-diatr Clin North Am, 2 (2000), pp. 353-372
[20.]
T.G. Boyce, W.C. Gruber, S.D. Coleman-Dockery, E.C. Sannella, G.W. Reed, M. Wolff, et al.
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children.
Vaccine, 18 (2000), pp. 82-88
[21.]
R.B. Belshe, P.M. Mendelman, J. Treanor, J. King, W.C. Gruber, P. Piedra, et al.
The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenza virus vaccine in children.
N Engl J Med, 338 (1998), pp. 1405-1412
[22.]
R.B. Belshe, W.C. Gruber, P.M. Mendelman, I. Cho, K. Reisinger, S.L. Block, et al.
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal Influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
J Pediatr, 136 (2000), pp. 168-175
[23.]
I.M. Longini Jr, M.E. Halloran, A. Nizam, M. Wolff, M. Mendelman, P.E. Fast, et al.
Estimation of the efficacy of live, attenuated Influenza vaccine from a two-year, multicenter vaccine trial: implications for Influenza epidemic control.
Vaccine, 18 (2000), pp. 1902-1909
[24.]
W.C. Gruber, P.M. Darden, G. Still, J. Lohr, G. Reed, F. Wright.
Evaluation of bivalent live attenuated InfluenzaA vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response.
Vaccine, 15 (1997), pp. 1379-1384
[25.]
W.A. Keitel, P.A. Piedra.
1998 Live cold-adapted, reassortant Influenza vaccines (USA).
Textbook of Influenza, pp. 373-390
[26.]
G.A. Poland, R. Couch.
Intranasal Influenzavaccine. Adding to the armamentarium for Influenza control.
Jama, 282 (1999), pp. 182-184
[27.]
L.V. Gubareva, L. Kaiser, F.G. Hayden.
Influenza virus neuraminidase inhibitors.
Lancet, 355 (2000), pp. 827-835
[28.]
Garau M, Moraga FA, Barroso C. Zanamivir. Pediatr Catalana 2000;60 (en prensa)
[29.]
F.G. Hayden, A. Osterhaus, J.J. Treanor, D.M. Fleming, F.Y. Aoki, K.G. Nicholson, et al.
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of Influenza virus infec-tions.
N Engl J Med, 337 (1997), pp. 874-880
[30.]
The MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of Influenza A and B virus infections.
Lancet, 352 (1998), pp. 1877-1881
[31.]
J.A. Hedrick, A. Barzilai, U. Behre, F.W. Henderson, J. Hammond, L. Reilly.
Zanamivir for treatment of symptomatic Influenza A and B infection in children five to twelve years of age: a ran-domized controlled trial.
Pediatr infect Dis J, 19 (2000), pp. 410-417
[32.]
A.S. Monto, D.P. Robinson, M.L. Herlocher, J.M. Hinson, M.J. Elliott, A. Crisp.
Zanamivir in the prevention of Influenza among he-althy adults. A randomized controlled trial.
Jama, 282 (1999), pp. 31-35
[33.]
J.J. Treanor, F.G. Hayden, P.S. Vrooman, R. Barbarash, R. Bettis, D. Riff, et al.
Efficacy and safety of the oral neuraminidase in-hibitor oseltamivir in treating acute Influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Jama, 283 (2000), pp. 1016-1024
[34.]
F.G. Hayden, R.L. Atmar, M. Schilling, C. Johnson, D. Poretz, D. Paar, et al.
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent Influenza.
N Engl J Med, 341 (1999), pp. 1336-1343
Copyright © 2002. Asociación Española de Pediatría
